Regorafenib for the treatment of unresectable hepatocellular carcinoma

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• De Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol. 2012;56(Suppl 1):S75–87.
   PubMed Web of Science ®Google Scholar
• EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. J Hepatol. 2012 Apr;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Hussain SA, Ferry DR, El-Gazzaz G, et al. Hepatocellular carcinoma. Ann Oncol. 2001;12:161–172.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
   PubMed Web of Science ®Google Scholar
• Mantovani A. Cancer: inflammation by remote control. Nature. 2005;435:752–753.
   PubMed Web of Science ®Google Scholar
• Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436–2443.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–4075.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–3524.
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–179.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559–566.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Niedzwieski D, Knox JJ, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol. 2016;34(Suppl):abstr4003.
   Google Scholar
• Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31:3509–3516.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. Jama. 2014;312:57–67.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Qin S, Ryoo BY, et al. Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2016;34(Suppl):abstr4017.
   Google Scholar
• Anon. A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein; [cited 2017 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02435433
   Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55–63.
   PubMed Web of Science ®Google Scholar
• Anon. Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy; [cited 2017 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01755767
   Google Scholar
• Anon. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma; [cited 2017 May 17]. Available from: http://investors.arqule.com/releasedetail.cfm?ReleaseID=1012374
   Google Scholar
• Anon. ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan; [cited 2017 May 17]. Available from: http://www.businesswire.com/news/home/20170327005077/en/
   Google Scholar
• Anon. Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib; [cited 2017 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01908426
   Google Scholar
• Anon. Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240); [cited 2017 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02702401
   Google Scholar
• Granito A, Marinelli S, Terzi E, et al. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis. 2015;47:518–522.
   PubMedGoogle Scholar
• Casadei Gardini A, Foca F, Scartozzi M, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep. 2017;7:42499.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290–2300.
   PubMed Web of Science ®Google Scholar
• Personeni N, Rimassa L, Santoro A. Biomarkers in hepatocellular carcinoma – letter. Clin Cancer Res. 2012;18:4861.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Abbadessa G, Personeni N, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget. 2016;7:72622–72633.
   PubMed Web of Science ®Google Scholar
• Personeni N, Giordano L, Abbadessa G, et al. Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. Oncotarget. 2017;8:14408–14415.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Chen D, He W, et al. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. J Hepatol. 2016;65:296–304.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs. 2012;21:879–889.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.
   PubMed Web of Science ®Google Scholar
• Zopf D, Heinig R, Thierauch K-H, et al. Regorafenib (BAY 73–4506): preclinical pharmacology and clinical identification and quantification of its major metabolites. Cancer Res. 2010;70(Suppl8):abstr1666.
   Google Scholar
• Mross K, Frost A, Steinbild S, et al. A Phase I dose–escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–2667.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
   PubMed Web of Science ®Google Scholar
• Ploeger B, Cleton A, Keunecke A, et al. Population pharmacokinetics (popPK) to evaluate the effect of intrinsic and extrinsic factors on regorafenib (REG) exposure in REG studies including patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2017;35(Suppl 4_suppl):320–320.
   Google Scholar
• Solms A, Ploeger B, Reinecke I, et al. Exposure-response (ER) relationship of regorafenib (REG) in patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2017;35(Suppl4S):abstr374.
   Google Scholar
• Anon. A Phase I, Randomized, Open Label, 3-Way Cross-Over Study to Determine the Effect of a High-Fat Breakfast, a Low-Fat Breakfast and Fasting State on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers; [cited 2017 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01002378
   Google Scholar
• Shimizu T, Tolcher AW, Patnaik A, et al. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J Clin Oncol. 2010;28(suppl; abstr 3035):15s.
   PubMed Web of Science ®Google Scholar
• Bayer Healtcare. Data on file; [cited 2017 May 17]. Available from: http://trialfinder.bayerscheringpharma.de/html/pdf/11651_Study_Synopsis_CTP.pdf
   Google Scholar
• Sunakawa Y, Furuse J, Okusaka T, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 2014;32:104–112.
   PubMed Web of Science ®Google Scholar
• Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicenter open label phase II safety study. Eur J Cancer. 2013;49:3412–3419.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
   PubMed Web of Science ®Google Scholar
• Bruix J, Merle P, Granito A, et al. Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo. J Clin Oncol. 2017;35(Suppl4S):abstr229.
   Google Scholar
• Finn RS, Merle P, Granito A, et al. Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): results of the international, randomized phase 3 RESORCE trial. J Clin Oncol. 2017;35(suppl4S):abstr344.
   Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Apr 20. pii: S0140-6736(17)31046-2 [Epub ahead of print]. DOI:10.1016/S0140-6736(17)31046-2.
   PubMedGoogle Scholar
• Anon. A Study of Nivolumab Compared to Sorafenib as a Primary Treatment in Patients With Advanced Hepatocellular Carcinoma; [cited 2017 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02576509
   Google Scholar
• Anon. A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma; [cited 2017 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01761266
   Google Scholar
• Anon. Phase III trial of anticancer agent Lenvima® as first-line treatment for unresectable hepatocellular carcinoma meets primary endpoint; [cited 2017 May 17]. Available from: http://www.eisai.com/news/enews201706pdf.pdf
   Google Scholar
• Jackson R, Psarelli EE, Berhane S, et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized Phase III trials. J Clin Oncol. 2017;35:622–628.
   PubMed Web of Science ®Google Scholar
• Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101–107.
   PubMed Web of Science ®Google Scholar
• Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013;58:2023–2031.
   PubMed Web of Science ®Google Scholar
• Iavarone M, Cabibbo G, Biolato M, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology. 2015;62:784–791.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Cole SR, Kirk GD, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611–622.
   PubMed Web of Science ®Google Scholar
• Puoti M, Rossotti R, Garlaschelli A, et al. Hepatocellular carcinoma in HIV hepatitis C virus. Curr Opin HIV AIDS. 2011;6:534–538.
   PubMed Web of Science ®Google Scholar
• Merchante N, Ibarra S, Revollo B, et al. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. Aids. 2017;31:89–95.
   PubMed Web of Science ®Google Scholar
• Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012;18:45–52.
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81–88.
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65:2457–2464.
   PubMed Web of Science ®Google Scholar
• Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(Suppl):abstr4007.
   Google Scholar